Dublin, Ireland-based Allergan plc is engaged in the development, manufacturing, marketing, sale and distribution of branded pharmaceuticals and select over-the-counter products.
Allergan has been actively pursuing deals to expand its portfolio especially its branded products offering. Having completed the acquisition of companies like Durata and Forest, Allergan acquired Botox maker, Allergan Inc., in Mar 2015. With this acquisition, Allergan, which was previously known for its strong presence in the generics market, finds itself in the company of the top 10 pharmaceutical companies across the world based on sales.
Allergan sold its generics and Anda distribution business to Teva in Aug and Oct 2016, respectively.
Allergan’s earnings performance has been mixed so far, with the company beating expectations in three of the past four quarters and missing on one occasion. The average negative earnings surprise over the last four quarters is 0.08%.
Currently, Allergan has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Allergan’s first-quarter earnings of $3.35 per share were above our consensus estimate of $3.32 per share.
Revenues Beat: Revenues also beat expectations. Revenues came in at $3.57 billion, up 5.1% from the year-ago period, and also beat the Zacks Consensus Estimate of $3.53 billion by 1.2%.
2017 Outlook Up: The company raised its previously issued earnings and sales guidance for 2017 to reflect contribution from the ZELTIQ Aesthetics acquisition
Allergan expects total revenue in a range of $15.8 billion to $16.0 billion for 2017 compared with $15.5 billion to $15.8 billion previously.
Adjusted earnings are expected in a range of $15.85–$16.35 compared to $15.80–$16.30 per share previously.
Share Price Impact: Shares were in-active in pre-market trading.
Check back later for our full write up on this AGN earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Image: Bigstock
Allergan (AGN) Beats Q1 Earnings & Sales; Ups 2017 View
Dublin, Ireland-based Allergan plc is engaged in the development, manufacturing, marketing, sale and distribution of branded pharmaceuticals and select over-the-counter products.
Allergan has been actively pursuing deals to expand its portfolio especially its branded products offering. Having completed the acquisition of companies like Durata and Forest, Allergan acquired Botox maker, Allergan Inc., in Mar 2015. With this acquisition, Allergan, which was previously known for its strong presence in the generics market, finds itself in the company of the top 10 pharmaceutical companies across the world based on sales.
Allergan sold its generics and Anda distribution business to Teva in Aug and Oct 2016, respectively.
Allergan’s earnings performance has been mixed so far, with the company beating expectations in three of the past four quarters and missing on one occasion. The average negative earnings surprise over the last four quarters is 0.08%.
Currently, Allergan has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Allergan’s first-quarter earnings of $3.35 per share were above our consensus estimate of $3.32 per share.
Revenues Beat: Revenues also beat expectations. Revenues came in at $3.57 billion, up 5.1% from the year-ago period, and also beat the Zacks Consensus Estimate of $3.53 billion by 1.2%.
2017 Outlook Up: The company raised its previously issued earnings and sales guidance for 2017 to reflect contribution from the ZELTIQ Aesthetics acquisition
Allergan expects total revenue in a range of $15.8 billion to $16.0 billion for 2017 compared with $15.5 billion to $15.8 billion previously.
Adjusted earnings are expected in a range of $15.85–$16.35 compared to $15.80–$16.30 per share previously.
Share Price Impact: Shares were in-active in pre-market trading.
Allergan PLC. Price and EPS Surprise
Allergan PLC. Price and EPS Surprise | Allergan PLC. Quote
Check back later for our full write up on this AGN earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>